101 Aufrufe 101 0 Kommentare 0 Kommentare

    Median Technologies Hosted Insightful Key Opinion Leader (KOL) Webinar on eyonis Lung Cancer Screening (LCS) REALITY Data

    Regulatory News:

    Median Technologies (FR0011049824, ALMDT, PEA/SME eligible, “Median” or “The Company”), a leading developer of eyonis, a suite of artificial intelligence (AI) powered Software as a Medical Device (SaMD) candidates for early cancer diagnostics, and a globally leading provider of AI analyses and imaging services for oncology drug developers, today announced that it hosted a successful event with two key opinion leaders (KOLs) in the field of pulmonology.

    Approximately 80 institutional investors, individual shareholders, analysts, journalists and other stakeholders attended the November 7 event. Two leading U.S. pulmonology experts Prof. Anil Vachani, from the Hospital of the University of Pennsylvania, and Prof. Javier Zulueta, from the Icahn School of Medicine at Mt Sinai, provided their views on the data from REALITY, Median’s recently completed pivotal study of the eyonis LCS SaMD, and how the AI powered device may impact lung cancer diagnostics and treatment. The data from REALITY will be included in filings for marketing authorizations in the US and in Europe in H1 2025. Fredrik Brag, CEO and founder of Median Technologies, presented results from the study at the event.

    “We are proud to have welcomed Prof. Vachani and Prof. Zulueta, two globally recognized experts in pulmonology, to Median’s event on our eyonis LCS diagnostic candidate. The REALITY study has shown that the AI-powered eyonis LCS device has considerable potential to address the urgent need for greater accuracy and efficiency to increase early detection of lung cancer. We discussed the urgent need to support radiologists in navigating complex and often inconclusive imaging data in order to roll out lung cancer screening to all those who can benefit. The REALITY study data suggest that eyonis LCS may well be a game changer by significantly improving early diagnosis, allowing for earlier intervention and broadening screening access—a critical step toward global implementation of these lifesaving programs. Based on our strong data, we are now looking towards our filings for marketing authorization, in both the US and Europe, in H1 2025, as soon as we receive and report the data from RELIVE, our second pivotal study,” said Fredrik Brag.

    Seite 1 von 3



    Business Wire (engl.)
    0 Follower
    Autor folgen

    Median Technologies Hosted Insightful Key Opinion Leader (KOL) Webinar on eyonis Lung Cancer Screening (LCS) REALITY Data Regulatory News: Median Technologies (FR0011049824, ALMDT, PEA/SME eligible, “Median” or “The Company”), a leading developer of eyonis, a suite of artificial intelligence (AI) powered Software as a Medical Device (SaMD) candidates for early cancer …